ArticleThe Lancet. Rheumatology2022
Immunogenicity and safety of two doses of the CoronaVac SARS-CoV-2 vaccine in SARS-CoV-2 seropositive and seronegative patients with autoimmune rheumatic diseases in Brazil: a subgroup analysis of a phase 4 prospective study.
Nadia E Aikawa et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
15 papers cite it
this papertrialcites it